Skip to main content
. 2019 Aug 15;42(10):942–951. doi: 10.1002/clc.23246

Table 1.

Characteristics of the included eight RCTs

No. of Article 1 2 3 4 5 6 7 8
First author Benjamin W. Van Tassell Allison C. Morton Antonio Abbate Antonio Abbate Antonio Abbate Robin P. Choudhury P.M. Ridker P.M. Ridker
Year 2017 2014 2010 2013 2015 2016 2017 2017
Region America UK America America America Canada,UK,America,Germany and Israel 39 Countries 39 Countries
Trial type RCT RCT RCT RCT RCT RCT RCT RCT
Drug Anakinra Anakinra Anakinra Anakinra Anakinra Canakinumab Canakinumab Canakinumab
Case(n[P/T]) 34(18/16) 182(89/93) 10(5/5) 30(15/15) 40(20/20) 189(94/95) 5628(3344/2284) 9534(3182/6352)
Age (P/T) 61(56‐68)/57(53‐66) 61.3(12.3)/61.4(11.7) 51.8(28‐65)/45.4(34‐59) 58.2(35‐83)/59.1(46‐86) 58(51‐65)/57(48‐60) 61.9(6.9)/61.7(7.8) 61.1(10.0)/61.2(10.0) 61.0(54.0‐68.0)/61.0(55.0‐68.0)(T1);61.0(54.0‐68.0)(T2)
Male (n[%]) (P/T) 13(72)/12(75) 67(75.3)/63(67.7) 5(100)/3(60) 13(86.7)/9(60.0) 18(90)/12(60) 80(85)/82(86) 2479(74.1)/1709(74.8) 2365(74)/4735(75)
BMI(kg/㎡) 30(27‐38)/36(29‐41) 28.4(4.7)/30.0(7.1) NA NA NA 30.3(4.0)/30.3(4.1) NA 29.7(26.6‐33.9)/30.5(27.0‐34.7)(T1);29.6(26.4‐33.1)(T2)
Hypertestion(%) (P/T) NA 29(32.6)/31 (33.3) 3(60)/5(100) 11(73.3)/7(46.7) 14 (70)/12(60) 83(88)/81(85) 2644(79.1)/1814(79.4) 2514(79)/5075(80)
Diabetes(%)(P/T) 12(67)/9(56) 8(9.0)/15(16.1) 1(20)/2(40) 3(20.0)/3(20.0) 4(20)/5(25) 81(86)/81(85) 1333(39.9)/1814(79.4) 1265(40)/2536(40)
CRP([mg/L])(P/T) 5.2(2.0‐11.9)/7.2(3.3‐12.3) 5.21(3.75, 7.22)/5.38(4.12, 7.04) NA 4.3(2.2‐7.5)/7.0(2.3‐8.7) NA 1.85(0.83‐3.88)/1.77(0.84‐3.74) 4.10(2.75‐6.85)/4.25(2.85‐7.05) 4.10(2.75–6.85)/5.55 (3.60‐9.25)(T1);3.40(2.45‐5.20)(T2)
End point All MACE
ALL death
AMI
UA
HF
All MACE
ALL death
AMI
All MACE
ALL death
AMI
UA
HF
All MACE
ALL death
AMI
UA
HF
All MACE
ALL death
AMI
UA
HF
All MACE
ALL death
AMI
UA
HF
All MACE
ALL death
AMI
UA
All MACE
ALL death

Abbreviations: AMI, acute myocardial infarction; AUC, area under curve; BMI, body‐mass index; CRP, C reactive protein; HF, heart failure; LVESVi, left ventricular end systolic volume index; MACE, major adverse cardiovascular event; NA, not available; P, placebo group; RCT, randomized controlled trial; T, test group; T1, test group1; T2, test group2; UA, unstable angina.